Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management

Acta Psychiatrica Scandinavica

Volumn 132, Issue 2, 2015, Pages 97-108

  Manu, P ^a,b,c   Dima, L ^d   Shulman, M ^a   Vancampfort, D ^e   De Hert, M ^f   Correll, C U ^a,b,c  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^d TRANSILVANIA UNIVERSITY OF BRASOV   (Romania)

^e KU LEUVEN DEPARTMENT OF REHABILITATION SCIENCES   (Belgium)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

management; obesity; pathobiology; schizophrenia; weight gain

Indexed keywords

AMISULPRIDE; ANTIOBESITY AGENT; ARIPIPRAZOLE; ASENAPINE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; HORMONE; ILOPERIDONE; LURASIDONE; NEUROLEPTIC AGENT; NEUROTRANSMITTER; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; SERTINDOLE; THIORIDAZINE; ZIPRASIDONE; ZOTEPINE;

ADULT; ARTICLE; BODY WEIGHT; CALORIC INTAKE; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENERGY EXPENDITURE; FEMALE; GENETIC SUSCEPTIBILITY; HOSPITAL READMISSION; HUMAN; HYPOTHALAMUS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; QUALITY OF LIFE; SCHIZOPHRENIA; SIDE EFFECT; SOCIAL PSYCHOLOGY; SOCIOECONOMICS; WEIGHT GAIN; LIFESTYLE; PATHOPHYSIOLOGY; PSYCHOLOGY; RISK FACTOR;

HUMANS; LIFE STYLE; OBESITY; QUALITY OF LIFE; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; WEIGHT GAIN;

EID: 84930260795     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/acps.12445     Document Type: Article

References (107)

1. Caemmerer J, Correll CU, Maayan L. Acute and maintenance effects on non-pharmacologic interventions for antipsychotics associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials. Schizophr Res 2012;140:159–168.
2. Manu P, Khan S, Radhakrishnan R, Russ MJ, Kane JM, Correll CU. Body mass index identified as an independent predictor of psychiatric readmission. J Clin Psychiatry 2014;75:e573–e577.
3. Correll CU, Lencz T, Malhotra AK. Antipsychotic drugs and obesity. Trends Mol Med 2011;17:97–107.
4. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2011;8:114–126.
5. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009;302:1765–1773.
6. Foley DL, Morley KI. Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. Arch Gen Psychiatry 2011;68:609–616.
7. Parin P. Abnormal nutritional states in schizophrenia. Schweiz Arch Neurol Psychiatr 1953;72:231–243.
8. Bruch H. Developmental obesity and schizophrenia. Psychiatry 1958;21:65–70.
9. Ng M, Fleming T, Robinson M et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014;384:766–781.
10. Jensen MD, Ryan DH, Apovian CM et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation 2014;129:S102–S138.
11. Maina G, Salvi V, Vitalucci A, D'Ambrosio V, Bogetto F. Prevalence and correlates of overweight in drug-naïve patients with bipolar disorder. J Affect Disord 2008;110:149–155.
12. de Hert M, Bobes J, Cetkovich-Bakmas M et al. Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, and recommendations at the system and individual level. World Psychiatry 2011;10:138–151.
13. de Hert M, Yu WP, Detraux J et al. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone, and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs 2012;26:733–759.
14. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373:31–41.
15. Rummel-Kluge C, Komossa K, Schwarz S et al. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull 2012;38:167–177.
16. Parsons B, Allison DB, Loebel A et al. Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr Res 2009;110:103–110.
17. Kahn RS, Fleischhacker WW, Boter H et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008;371:1085–1097.
18. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects. A comprehensive literature review. CNS Drugs 2005;19:1–93.
19. Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209–1223.
20. Bushe CJ, Slooff CJ, Haddad PM, Karagianis JL. Weight change from 3-year observational data: findings from the worldwide schizophrenia outpatient health outcomes database. J Clin Psychiatry 2012;73:749–755.
21. Tarricone I, Ferrari-Gozzi B, Serretti A, Grieco D, Berardi D. Weight gain in antipsychotic-naive patients: a review and meta-analysis. Psychol Med 2010;40:187–200.
22. Alvarez-Jiménez M, Gonzales-Blanch C, Crespo-Facorro B et al. Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal. CNS Drugs 2008;22:547–562.
23. Strassnig M, Miewald J, Keshavan M, Ganguli R. Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis. Schizophr Res 2007;93:90–98.
24. Bak M, Fransen A, Janssen J, van Os J, Drukker M. Almost all antipsychotics result in weight gain: a meta-analysis. PLoS ONE 2014;9:e94122.
25. Perez-Iglesias R, Ortiz-Garcia De La Foz V, Martinez Garcia O et al. Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12 weeks of treatment in first treated episode of psychosis. Schizophr Res 2014;159:90–94.
26. Citrome L, Holt RI, Walker DJ, Hoffmann VP. Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder. Clin Drug Investig 2011;31:455–482.
27. Kinon BJ, Kaiser CJ, Ahmed S, Rotelli MD, Kollack-Walker S. Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol 2005;25:255–258.
28. Correll CU, Penzer JB, Parikh UH et al. Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatr Clin N Am 2006;15:177–206.
29. Correll CU, Sheridan EM, Delbello MP. Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials. Bipolar Disord 2010;12:116–141.
30. De Hert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry 2011;26:144–158.
31. Coccurello R, Caprioli A, Ghiranti O et al. Chronic administration of olanzapine induces metabolic and food intake alterations: a mouse model of the atypical antipsychotic-associated adverse effects. Psychopharmacology 2006;186:561–571.
32. Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders – a PRISMA meta-analysis. Schizophr Bull 2013;39:306–318.
33. Kryzhanovskaya LA, Xu W, Millen BA, Acharya N, Jen KY, Osuntokun O. Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapine. J Child Adolesc Psychopharmacol 2012;22:157–165.
34. Maayan L, Correll CU. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol 2011;21:517–535.
35. Fraguas D, Correll CU, Merchan-Naranjo J et al. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharmacol 2011;21:621–645.
36. Allison DB, Loebel AD, Lombardo I, Romano SJ, Siu CO. Understanding the relationship between baseline BMI and subsequent weight change in antipsychotic trials: effect modification or regression to the mean? Psychiatry Res 2009;170:172–176.
37. Bushe CJ, Slooff CJ, Haddad PM, Karagianis JL. Weight change by baseline BMI from three-year observational data: findings from the Worldwide Schizophrenia Outpatient Health Outcomes Database. J Psychopharmacol 2013;27:358–365.
38. Miller BA, Campbell GM, Beasley CM. Weight changes over time in adults treated with the oral or depot formulations of olanzapine; a pooled analysis of 86 clinical trials. J Psychopharmacol 2011;25:639–645.
39. Skolnik NS, Ryan DH. Pathophysiology, epidemiology, and assessment of obesity in adults. J Fam Pract 2014;63:S3–S10.
40. Nurjono M, Neelamekam S, Lee J. Serum leptin and its relationship with psychopathology in schizophrenia. Psychoneuroendocrinology 2014;50C:149–154.
41. Cortes B, Becker J, Mories Alvarez MT, Marcos AI, Molina V. Contribution of baseline body mass index and leptin serum level to the prediction of early weight gain with atypical antipsychotics in schizophrenia. Psychiatry Clin Neurosci 2014;68:127–132.
42. Donnelly JE, Blair SN, Jakicic JM, Manore MM, Rankin JW, Smith BK. American College of Sports Medicine Position Stand. Appropriate physical activity intervention strategies for weight loss and prevention of weight regain for adults. Med Sci Sports Exerc 2009;41:459–471.
43. Dipasquale S, Pariante CM, Dazzan P, Aguglia E, McGuire P, Mondelli V. The dietary pattern of patients with schizophrenia: a systematic review. J Psychiatr Res 2013;47:197–207.
44. Manzanares N, Monseny R, Ortega L et al. Unhealthy lifestyles in early psychoses: the role of life stress and the hypothalamic-pituitary-adrenal axis. Psychoneuroendocrinology 2014;39:1–10.
45. Nunes D, Eskinazi B, Camboim Rockett F, Delgado VB, Schweigert Perry ID. Nutritional status, food intake and cardiovascular disease risk in individuals with schizophrenia in southern Brazil: a case-control study. Rev Psiquiatr Salud Ment 2014;7:72–79.
46. Coccurello R, Moles A. Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design. Pharmacol Ther 2010;127:210–251.
47. Smith GC, Vickers MH, Shepherd PR. Olanzapine effects on body composition, food preference, glucose metabolism and insulin sensitivity in the rat. Arch Physiol Biochem 2011;117:241–249.
48. Gothelf D, Falk B, Singer P et al. Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psychiatry 2002;159:1055–1057.
49. Cuerda C, Merchan-Naranjo J, Velasco C et al. Influence of resting energy expenditure on weight gain in adolescents taking second-generation antipsychotics. Clin Nutr 2011;30:616–623.
50. Rodriguez G, Moreno LA, Sarria A, Fleta J, Bueno M. Determinants of resting energy expenditure in obese and non-obese children and adolescents. J Physiol Biochem 2002;58:9–15.
51. Sharpe JK, Byrne NM, Stedman TJ, Hills AP. Resting energy expenditure is lower than predicted in people taking atypical antipsychotic medication. J Am Diet Assoc 2005;105:612–615.
52. Sharpe JK, Stedman TJ, Byrne NM, Hills AP. Low-fat oxidation may be a factor in obesity among men with schizophrenia. Acta Psychiatr Scand 2009;119:451–456.
53. Graham KA, Perkins DO, Edwards LJ, Barrier RC Jr, Lieberman JA, Harp JB. Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. Am J Psychiatry 2005;162:118–123.
54. Ehrlich S, Leopold K, Merle JV et al. Trajectories of agouti-related protein and leptin levels during antipsychotic-associated weight gain in patients with schizophrenia. J Clin Psychopharmacol 2012;32:767–772.
55. Weston-Green K, Huang XF, Deng C. Alterations to melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapine-induced weight gain. PLoS ONE 2012;7:e33548.
56. Zhang Q, He M, Deng C, Wang H, Lian J, Huang XF. Hypothalamic ghrelin signaling mediates olanzapine-induced hyperphagia and weight gain in female rats. Int J Neuropsychopharmacol 2014;17:807–818.
57. Hanssens L, van Winkel R, Wampers M et al. A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder. Schizophr Res 2008;106:308–314.
58. Bai YM, Chen TT, Yang WS et al. Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: a cohort study. Schizophr Res 2009;111:1–8.
59. Wampers M, Hanssens L, van Winkel R et al. Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: results from a 3-month prospective open-label study. Eur Neuropsychopharmacol 2012;22:17–26.
60. Song X, Fan X, Song X et al. Elevated levels of adiponectin and other cytokines in drug naïve, first episode schizophrenia patients with normal weight. Schizophr Res 2013;150:269–273.
61. Kroeze WK, Hufeisen SJ, Popadak BA et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003;28:519–526.
62. Kim SF, Huang AS, Snowman AM et al. From the Cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci USA 2007;104:3456–3459.
63. Deng C, Weston-Green K, Huang XF. The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain? Prog Neuropsychopharmacol Biol Psychiatry 2010;34:1–4.
64. He M, Zhang O, Deng C, Wang H, Lian J, Huang XF. Hypothalamic histamine H1 receptor-AMPK signaling time-dependently mediates olanzapine-induced hyperphagia and weight gain in female rats. Psychoneuroendocrinology 2014;42:153–164.
65. Lian J, Huang XF, Pai N, Deng C. Preventing olanzapine-induced weight gain using betahistine: a study in a rat model with chronic olanzapine treatment. PLoS ONE 2014;9:e104160.
66. Poyurovsky M, Fuchs C, Pashinian A, Levi A, Weizman R, Weizman A. Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine–betahistine combination. Psychopharmacology 2013;226:615–622.
67. Malhotra AK, Correll CU, Chowdhury NI et al. Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Arch Gen Psychiatry 2012;69:904–912.
68. Tiwari AK, Brandl EJ, Weber C et al. Association of a functional polymorphism in neuropeptide Y with antipsychotic-induced weight gain in schizophrenia patients. J Clin Psychopharmacol 2013;33:11–17.
69. Souza RP, Tiwari AK, Chowdhury NI et al. Association study between variants of AMP-activated protein kinase catalytic and regulatory subunit genes with antipsychotic-induced weight gain. J Psychiatr Res 2012;46:462–468.
70. Houston JP, Kohler J, Bishop JR et al. Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia. J Clin Psychiatry 2012;73:1077–1086.
71. Moons T, Claes S, Martens GJ et al. Clock genes and body composition in patients with schizophrenia under treatment with antipsychotic drugs. Schizophr Res 2011;125:187–193.
72. Manu P, Correll CU, Wampers M et al. Markers of inflammation in schizophrenia: association vs. causation. World Psychiatry 2014;13:189–192.
73. Wang YC, Bai YM, Chen JY, Lin CC, Lai IC, Liou YJ. Genetic association between TNF-alpha-308 G>A polymorphism and longitudinal weight change during clozapine treatment. Hum Psychopharmacol 2010;25:303–309.
74. Huang HH, Wang YC, Wu CL et al. TNF-a-308 G>A polymorphism and weight gain in patients with schizophrenia under long-term clozapine, risperidone or olanzapine treatment. Neurosci Lett 2011;504:277–280.
75. Daumit GL, Dickerson FB, Wang NY et al. A behavioral weight-loss intervention in persons with serious mental illness. N Engl J Med 2013;368:1594–1602.
76. Agerbo E, Byrne M, Eaton WW, Mortensen PB. Marital and labor market status in the long run in schizophrenia. Arch Gen Psychiatry 2004;61:28–33.
77. Thornicroft G, Brohan E, Rose D, Sartorius N, Leese M, INDIGO Study Group. Global pattern of experienced and anticipated discrimination against people with schizophrenia: a cross-sectional survey. Lancet 2009;373:408–415.
78. Mueser KT, McGurk SR. Schizophrenia. Lancet 2004;363:2063–2072.
79. Kushner RF, Sur DK. Principles and nonpharmacologic management of obesity in adults. J Fam Pract 2014;63:S15–S20.
80. Ajala O, English P, Pinkney J. Systematic review and meta-analysis of different dietary approaches to the management of type 2 diabetes. Am J Clin Nutr 2013;97:505–516.
81. Look AHEAD Research Group, Pi-Sunyer X, Blackburn G et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care 2007;30:1374–1383.
82. Ryan D. The pharmacological and surgical management of adults with obesity. J Fam Pract 2014;63:S21–S26.
83. Aronne LJ. Evolving directions in obesity management. J Fam Pract 2014;63:S27–S33.
84. Boland CL, Harris JB, Harris KB. Pharmacological management of obesity in pediatric patients. Ann Pharmacother 2014;3:pii1060028014557859 [Epub ahead of print].
85. Maayan L, Vakhrusheva J, Correll CU. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology 2010;35:1520–1530.
86. Campos C. Tips for communicating with overweight and obese patients. J Fam Pract 2014;63:S11–S14.
87. Maayan L, Correll CU. Management of antipsychotic-related weight gain. Expert Rev Neurother 2010;10:1175–1200.
88. Hasnain M, Fredrickson SK, Vieweg WV, Pandurangi AK. Metabolic syndrome associated with schizophrenia and atypical antipsychotics. Curr Diab Rep 2010;10:209–216.
89. Vreeland B. Treatment decisions in major mental illness: weighing the outcomes. J Clin Psychiatry 2007;68:5–11.
90. Green CA, Yarborough BJH, Leo MC et al. The STRIDE weight loss and lifestyle intervention for individuals taking antipsychotic medications: a randomized trial. Am J Psychiatry 2015;172:71–81.
91. Correll CU. From receptor pharmacology to improved outcomes: individualizing the selection, dosing, and switching of antipsychotics. Eur Psychiatry 2010;25:S12–S21.
92. Hermes E, Nasrallah H, Davis V et al. The association between weight change and symptom reduction in the CATIE schizophrenia trial. Schizophr Res 2011;128:166–170.
93. Mukundan A, Faulkner G, Cohn T, Remington G. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database Syst Rev 2010;12:CD006629.
94. Stroup TS, McEvoy JP, Ring KD et al. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry 2011;168:947–956.
95. Newcomer JW, Campos JA, Marcus RN et al. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. J Clin Psychiatry 2008;69:1046–1056.
96. Meyer JM, Davis VG, Goff DC et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE schizophrenia trial: prospective data from phase 1. Schizophr Res 2008;101:273–286.
97. Weiden PJ, Newcomer JW, Loebel AD, Yang R, Lebovitz HE. Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. Neuropsychopharmacology 2008;33:985–994.
98. Gallego JA, Nielsen J, De Hert M, Kane JM, Correll CU. Safety and tolerability of antipsychotic polypharmacy. Expert Opin Drug Saf 2012;11:527–542.
99. Chen Y, Bobo WV, Watts K, Jayathilake K, Tang T, Meltzer HY. Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia; a 12-month, prospective, open-label study. J Psychopharmacol 2012;26:1201–1210.
100. Mizuno Y, Suzuki T, Nakagawa A et al. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull 2014;17:1–19.
101. Correll CU, Sikich L, Reeves G, Riddle M. Metformin for antipsychotic related weight gain and metabolic abnormalities: when, how long and for whom? Am J Psychiatr 2013;170:947–952.
102. Dehert M, Correll CU, Bobes J et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 2011;10:52–77.
103. Leucht S, Burkard T, Henderson J, Maj M, Sartorius N. Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand 2007;116:317–333.
104. Köster LS, Carbon M, Correll CU. Emerging drugs for schizophrenia: an update. Expert Opin Emerg Drugs 2014;19:511–531.
105. Tiihonen J, Lönnqvist J, Wahlbeck K et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009;374:620–627.
106. Torniainen M, Mittendorfer-Rutz E, Tanskanen A et al. Antipsychotic treatment and mortality in schizophrenia. Schizophr Bull 2014;41:656–663.
107. Correll CU, Detraux J, De Lepeliere J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on physical illness in patients with schizophrenia, depression and bipolar disorder. World Psychiatry. in press.